ZURICH, July 21 (Reuters) – Novartis (NOVN.S) is still helping CureVac (5CV.DE) make COVID-19 vaccines and could expand its capacity to assist other vaccine manufacturers as well, finance chief Harry Kirsch told reporters on Wednesday.
“We have started the production as planned. We are planning to deliver 50 million doses this year,” Kirsch said of the CureVac deal when asked whether it could instead make its capacity free for others after CureVac said last month its COVID-19 jab was only 48% effective. read more
Reporting by Michael Shields and Patricia Weiss, editing by John Revill
Our Standards: The Thomson Reuters Trust Principles.